Drug intelligence / Profile preview

RQ-2700

Development stage: Preclinical
Lead developer: Shanghai Lanque Biomedical
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

RQ-2700 is an mRNA-based immunotherapy being developed by RNAcure for the treatment of Human papillomavirus (HPV)-related diseases. As an mRNA therapeutic, it is designed to deliver genetic instructions to the patient's cells to produce specific HPV antigens, thereby stimulating a targeted immune response against HPV-infected cells. This approach aims to treat existing HPV infections and associated lesions or malignancies by leveraging the body's own immune system to recognize and eliminate virally infected or transformed cells.

Beyond the preview

Go deeper on RQ-2700.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RQ-2700.

Explore the full profile